Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Hum Gene Ther ; 12(1): 77-86, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11177545

ABSTRACT

Peripheral nervous system (PNS) sensory neurons are directly involved in the pathophysiology of numerous inherited and acquired neurological conditions. Therefore, efficient and stable gene delivery to these postmitotic cells has significant therapeutic potential. Among contemporary vector systems capable of neuronal transduction, only those based on herpes simplex virus have been extensively evaluated in PNS neurons. We therefore investigated the transduction performance of recombinant adeno-associated virus type 2 (AAV) and VSV-G-pseudotyped lentivirus vectors derived from human immunodeficiency virus (HIV-1) in newborn mouse and fetal human dorsal root ganglia (DRG) sensory neurons. In dissociated mouse DRG cultures both vectors achieved efficient transduction of sensory neurons at low multiplicities of infection (MOIs) and sustained transgene expression within a 28-day culture period. Interestingly, the lentivirus vector selectively transduced neurons in murine cultures, in contrast to human cultures, in which Schwann and fibroblast-like cells were also transduced. Recombinant AAV transduced all three cell types in both mouse and human cultures. After direct microinjection of murine DRG explants, maximal transduction efficiencies of 20 and 200 transducing units per neuronal transductant were achieved with AAV and lentivirus vectors, respectively. Most importantly, both vectors achieved efficient and sustained transduction of human sensory neurons in dissociated cultures, thereby directly demonstrating the exciting potential of these vectors for gene therapy applications in the PNS.


Subject(s)
Dependovirus/genetics , Ganglia, Spinal/virology , Lentivirus/genetics , Membrane Glycoproteins , Neurons, Afferent/virology , Recombinant Proteins/genetics , Transduction, Genetic , Animals , Cells, Cultured , Gene Expression , Gene Targeting/methods , Gene Transfer Techniques , Genetic Vectors , Green Fluorescent Proteins , Humans , Immunoenzyme Techniques , Infant, Newborn , Luminescent Proteins/metabolism , Mice , Microscopy, Fluorescence , Recombinant Proteins/metabolism , Viral Envelope Proteins/metabolism
2.
Hum Gene Ther ; 11(4): 629-35, 2000 Mar 01.
Article in English | MEDLINE | ID: mdl-10724041

ABSTRACT

Recombinant adeno-associated virus (rAAV) shows significant promise as a vector for gene transfer in pre-clinical models of human disease, and is currently being evaluated in human clinical trials. As a consequence, increasing attention is being turned to the important tasks of optimizing rAAV titer, purity, and stability. We have observed dramatic variation in divalent cation dependence for thermostability of different rAAV vectors. To further investigate this observation, the thermostability of eight different vector constructs ranging in size from 73 to 107% of wild-type genome size (4.68 kilobases) was determined in the presence and absence of divalent cations. Virions containing smaller genomes (i.e., <85% wild type) were relatively divalent cation independent for thermostability. In contrast, virions containing recombinant genomes close to, or exceeding, wild-type size (i.e., >95% wild type) were dependent on divalent cations for thermostability. Genome sequence also appeared to be a factor in the thermostability of the larger rAAV vectors. These observations are of both practical and theoretical significance. Divalent cations should be included in all buffer solutions used during rAAV purification and storage, and unnecessary heat exposure avoided. These data also demonstrate that different recombinants of a particular virus should not be assumed to possess the same thermostability profile.


Subject(s)
Dependovirus/genetics , Genetic Vectors , Cations, Divalent , Cell Line , Dependovirus/isolation & purification , Genome, Viral , Hot Temperature , Humans , Models, Genetic , Recombination, Genetic
3.
Gene Ther ; 6(5): 845-53, 1999 May.
Article in English | MEDLINE | ID: mdl-10505110

ABSTRACT

Dendritic cells (DC) are among the most potent antigen-presenting cells known and play an important role in the initiation of antigen-specific T-lymphocyte responses. Several recent studies have demonstrated that DC expressing vector-encoded tumor-associated antigens can induce protective and therapeutic immunity in murine cancer models. In the current study we set out to examine in vitro the utility of adenovirus vectors in the transduction of human DC for the induction of antigen-specific T-lymphocyte responses against a defined vector-encoded antigen. DC were derived from the adherent fraction of PBMC by culture in defined medium containing GM-CSF and IL-4. A replication-defective E1/E3-deleted type 5 adenovirus vector encoding bacterial beta-galactosidase (beta-gal) under the transcriptional control of a CMV promoter was used to transduce DC at multiplicities of infection (MOI) up to 1000. While high MOI were required to achieve efficient transduction there was no significant effect on DC morphology, immunophenotype or potency in allogeneic lymphocyte proliferation assays. Furthermore, transduced DC-induced antigen-specific CTL activity against adenoviral proteins and more significantly, the vector-encoded antigen beta-gal. These data clearly demonstrate the potential of adenovirus vectors in anticancer DC vaccine strategies and provide an important link between existing animal data and human clinical application.


Subject(s)
Adenoviridae/genetics , Dendritic Cells/immunology , Genetic Therapy/methods , Genetic Vectors/immunology , T-Lymphocytes, Cytotoxic/immunology , Transfection/methods , Cancer Vaccines/immunology , Cells, Cultured , Flow Cytometry , Fluorescent Antibody Technique, Indirect , Gene Expression , Humans , Microscopy, Confocal , beta-Galactosidase/immunology
4.
J Immunol ; 163(6): 3239-49, 1999 Sep 15.
Article in English | MEDLINE | ID: mdl-10477593

ABSTRACT

Augmenting immunogenicity by genetically modifying tumor cells to express costimulatory molecules has proven to be a promising therapeutic strategy in murine tumor models and is currently under investigation in human clinical trials for metastatic cancer. However, there are significant technical and logistic problems associated with implementing strategies requiring direct gene modification of primary tumor cells. In an effort to circumvent these problems, we are developing a strategy in which the costimulatory signal required for tumor-specific T lymphocyte activation is provided by a genetically modified human fibroblast (trans-costimulation). We have evaluated the efficiency of CD80- and CD86-mediated trans-costimulation in the activation of human CD8+ and CD4+ T lymphocytes in MHC class I- and class II-restricted lymphoproliferation reactions. Our studies demonstrate that the efficiency of CD80- or CD86-mediated trans-costimulation of purified human CD8+ and CD4+ T lymphocytes is comparable to cis-costimulation under defined conditions. Moreover, a dose-response relationship consistent with the predicted two-hit kinetics of the reaction was evident in trans-costimulation reactions in which the ratio of target cells expressing either signal 1 or signal 2 was varied incrementally from 1:10 to 10:1. Importantly, the level of cell-surface CD86 required for trans-costimulation is equivalent to that constitutively expressed by human peripheral blood monocytes. These results may have significant implications for the clinical implementation of this type of cancer immunotherapy and also raise questions about the possibility of trans-costimulating autoreactive T lymphocytes in vivo.


Subject(s)
Antigens, CD/genetics , B7-1 Antigen/genetics , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/genetics , Fibroblasts/immunology , Fibroblasts/metabolism , HLA Antigens/genetics , Lymphocyte Activation/genetics , Membrane Glycoproteins/genetics , 3T3 Cells , Animals , Antigens, CD/biosynthesis , Antigens, CD/physiology , Autoimmune Diseases/genetics , Autoimmune Diseases/therapy , B7-1 Antigen/physiology , B7-2 Antigen , Cell Separation , Cells, Cultured , Dose-Response Relationship, Immunologic , Female , Gamma Rays , Gene Expression Regulation/radiation effects , Genetic Vectors/chemical synthesis , Genetic Vectors/immunology , Histocompatibility Antigens Class I/biosynthesis , Histocompatibility Antigens Class I/physiology , Histocompatibility Antigens Class II/biosynthesis , Histocompatibility Antigens Class II/physiology , Humans , Kinetics , Leukocytes, Mononuclear/immunology , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/physiology , Mice , Retroviridae/genetics , Sarcoma, Alveolar Soft Part/genetics , Sarcoma, Alveolar Soft Part/immunology , Sarcoma, Alveolar Soft Part/therapy , Transgenes/radiation effects , Tumor Cells, Cultured
5.
AIDS Res Hum Retroviruses ; 15(5): 429-34, 1999 Mar 20.
Article in English | MEDLINE | ID: mdl-10195752

ABSTRACT

The 33-amino acid peptide K10-K42 has previously been described as having potent anti-HIV-1 activity, and antiviral efficacy against hepatitis B and human cytomegalovirus in vitro. Although the exact mechanism of antiviral activity was unknown, it was hypothesised that the K10-K42 peptide inhibited HIV-1 by interfering with one or more of the intracellular processes of reverse transcription, integration, and/or viral gene expression. We performed a series of experiments to identify and characterize the inhibitory mechanism, and to determine whether intracellular expression of the K10-K42 peptide would potentiate its antiviral efficacy in vitro. Surprisingly, our results revealed that the antiviral activity of the K10-K42 peptide could be explained without implicating intracellular inhibition of HIV-1 replication. The activity appeared to be due to an extraordinary capacity of the K10-K42 peptide to precipitate viral and nonviral proteins in vitro. The protein-precipitating capacity of the K10-K42 peptide was sequence specific and a scrambled version of the 33-amino acid peptide did not retain the activity. Although the unusual biochemical properties of the K10-K42 peptide probably negate a number of potential therapeutic applications, they do merit further investigation. Moreover, these findings provide a plausible explanation of the mechanism by which the K10-K42 peptide can inhibit replication of viruses from families as genetically and functionally diverse as Retroviridae, Hepadnaviridae, and Herpesviridae.


Subject(s)
Anti-HIV Agents/pharmacology , HIV-1/physiology , Peptides/pharmacology , Plant Proteins/chemistry , Virus Replication/drug effects , Amino Acid Sequence , Cells, Cultured , Chemical Precipitation , Electrophoresis, Polyacrylamide Gel , HIV-1/drug effects , Humans , Molecular Sequence Data , Peptides/chemistry , Ribosome Inactivating Proteins, Type 1 , Spectrophotometry , Viral Proteins/chemistry
6.
Mol Pathol ; 52(5): 289-94, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10748879

ABSTRACT

AIMS: To investigate multiple techniques for the preparation of solid tissue for polymerase chain reaction (PCR) analysis, and to identify the most simple techniques for routine use in the laboratory. METHODS: Techniques for the preparation of arterial tissue samples including homogenisation, ultrafiltration, and treatments involving proteinase K, Gene Clean, lectin, and Fe3+ specific chelators were evaluated using the PCR to amplify both Chlamydia pneumoniae and human DNA. RESULTS: Treatment with either Gene-Clean or lectin and the Fe3+ specific chelator deferoxamine mesylate removed PCR inhibitors from tissue homogenates. Homogenisation followed by GeneClean treatment resulted in the amplification of C pneumoniae DNA from within a section of atherosclerotic carotid artery, implying that C pneumoniae elementary bodies had been disrupted. In eight further clinical samples from patients not known to have C pneumoniae infection, human DNA was amplified and no cross contamination was observed between samples. These samples contained no evidence of C pneumoniae by PCR. CONCLUSIONS: A simple preparation of solid tissue for PCR analysis, involving homogenisation followed by GeneClean treatment has been developed, and is effective for the amplification of both C pneumoniae and human DNA.


Subject(s)
Arteries/microbiology , Arteriosclerosis/microbiology , Chlamydophila pneumoniae/isolation & purification , DNA, Bacterial/analysis , Polymerase Chain Reaction/methods , DNA/analysis , Evaluation Studies as Topic , Humans , Specimen Handling/methods
7.
J Immunol ; 160(11): 5390-6, 1998 Jun 01.
Article in English | MEDLINE | ID: mdl-9605139

ABSTRACT

In the process of developing a cancer immunotherapy strategy, we have identified and characterized a novel intracellular reservoir of CD86 protein in peripheral blood monocytes. This observation emerged from studies aimed at using retrovirus vectors to genetically modify tumor cells to express the costimulatory proteins CD80 and CD86. Retrovirus-mediated expression of CD80 and CD86 in T lymphoblastoid CEM cells resulted in an unexpected intracellular focal concentration of both proteins in the genetically modified cells. By extending these studies to an analysis of CD80 and CD86 expression in PBMC, we observed that endogenous CD86 expression in peripheral blood monocytes also involved a similar intracellular focal concentration of the protein. The intracellular concentration of CD86 in monocytes was not due to storage within the Golgi apparatus, and required intact microtubules to retain structural integrity. Furthermore, as the intensity of CD86 fluorescence increased on monocytes as a function of time in vitro, the intracellular focal concentration correspondingly decreased. These results are consistent with antegrade CD86 transport from an intracellular reservoir to the cell surface membrane. In this report, we detail the intracellular and membrane localization studies with tumor cell lines and PBMC, and describe the temporal relationship between intracellular storage and trafficking of CD86 to the cell surface membrane in peripheral blood monocytes. We hypothesize that this intracellular reservoir allows rapid and sustained deployment of an important costimulatory molecule to the monocyte surface membrane during initiation and maturation of the cell-mediated immune response.


Subject(s)
Antigens, CD/metabolism , Golgi Apparatus/immunology , Intracellular Fluid/immunology , Membrane Glycoproteins/metabolism , Monocytes/metabolism , Antigens, CD/biosynthesis , Antigens, CD/chemistry , B-Lymphocytes/metabolism , B7-1 Antigen/biosynthesis , B7-1 Antigen/metabolism , B7-2 Antigen , CD4 Antigens/metabolism , Clone Cells/chemistry , Golgi Apparatus/metabolism , HeLa Cells , Humans , Intracellular Fluid/chemistry , Intracellular Fluid/metabolism , Lymphocyte Activation , Macrophage-1 Antigen/metabolism , Membrane Glycoproteins/biosynthesis , Membrane Glycoproteins/chemistry , Membrane Proteins/biosynthesis , Membrane Proteins/metabolism , Microscopy, Confocal , Microscopy, Fluorescence , Microtubules/physiology , Monocytes/immunology , Muromonab-CD3/pharmacology , T-Lymphocytes/immunology , Transduction, Genetic/immunology , Tumor Cells, Cultured
9.
Proc Natl Acad Sci U S A ; 91(9): 3657-61, 1994 Apr 26.
Article in English | MEDLINE | ID: mdl-8170964

ABSTRACT

One strategy for somatic gene therapy for human immunodeficiency virus type 1 (HIV-1) infection is based on the regulated expression of dominant negative mutants of the HIV-1 gag gene. To limit expression of the mutant Gag polypeptide to HIV-1-infected cells, we have constructed a replication-defective retroviral vector that contains a Rev-responsive element. By using this construct we have obviated problems that can be associated with constitutive expression of an exogenous gene, an important step toward developing a human therapy. In uncloned T lymphocytes infected (transduced) with this retroviral construct, HIV-1 replication was inhibited by 94% with a concomitant decrease in the cytopathic effects of the virus. In addition, simian immunodeficiency virus (SIV) replication was also shown to be significantly inhibited, suggesting that this mutant Gag protein may have antiviral efficacy against a broad range of primate lentiviruses and that an SIV/macaque model can be used for further in vivo studies. These results have important implications in assessing the potential of somatic gene therapy in the treatment of HIV-1 infection.


Subject(s)
Genes, gag , Genes, rev , HIV Infections/therapy , T-Lymphocytes/microbiology , Amino Acid Sequence , Base Sequence , Gene Expression Regulation, Viral , Genetic Therapy , HIV-1/genetics , HIV-1/growth & development , HeLa Cells , Humans , In Vitro Techniques , Molecular Sequence Data , Mutation , RNA, Viral/genetics , Simian Immunodeficiency Virus/genetics , Simian Immunodeficiency Virus/growth & development , Transduction, Genetic , Virus Replication
10.
Protein Eng ; 7(2): 145-7, 1994 Feb.
Article in English | MEDLINE | ID: mdl-8170917

ABSTRACT

It has been demonstrated previously that molecular decoys of the acetylcholine receptor have therapeutic efficacy as antitoxins [Gershoni, J. and Aronheim, A. (1988) Proc. Natl Acad. Sci. USA, 85, 4087-4089], but surely a most challenging goal is to apply this approach towards the development of antiviral drugs. As viruses present multiple copies of their envelope proteins, it was proposed that polyvalent decoys could be advantageous. Here we report the design and expression of recombinant linear polymers of the HIV gp120-binding domains which are situated within the T-cell membrane protein CD4. Whereas the production of linear concatemers of CD4 variable domains is feasible, a number of conformational constraints must be considered when designing a polymeric molecule which retains biological function. Most significant is the contribution of domains flanking the binding site that apparently enable correct folding of the latter.


Subject(s)
Antiviral Agents/metabolism , CD4 Antigens/metabolism , HIV Envelope Protein gp120/metabolism , Protein Engineering , Recombinant Fusion Proteins/metabolism , Antiviral Agents/chemistry , Plasmids , Polymers , Protein Binding
11.
Infect Immun ; 59(7): 2403-11, 1991 Jul.
Article in English | MEDLINE | ID: mdl-1711015

ABSTRACT

Saimiri sciurus monkeys were immunized at multiple sites with recombinant vaccinia viruses expressing Plasmodium falciparum antigen genes and boosted 4 weeks later. Control monkeys were immunized with a thymidine kinase-negative vaccinia virus mutant. Two weeks later, all of the monkeys were challenged by intravenous inoculation of P. falciparum (Indochina strain) parasites. A group of unimmunized monkeys was challenged in parallel. All of the monkeys that received vaccinia virus recombinants or the control virus produced good anti-vaccinia virus antibody responses. However, those that received a single construct containing ring-infected erythrocyte surface antigen (RESA) given at eight sites did not produce significant antibody to any of the three major RESA repeat epitopes after immunization but were primed for an enhanced antibody response after challenge infection with P. falciparum. Most of the monkeys produced detectable antibodies to the RESA epitopes after challenge infection. One group of monkeys was immunized with four constructs (expressing RESA, two merozoite surface antigens [MSA-1 and MSA-2], and a rhoptry protein [AMA-1]), each given at two sites. While these monkeys failed to produce significant antibody against MSA-2 or AMA-1 after immunization, they produced enhanced responses against these antigens after challenge infection. Immunization involved an allelic form of MSA-2 different from that present in the parasite challenge strain, so that the enhanced responses seen after challenge infection indicated the presence of T-cell epitopes common to both allelic forms. No groups of monkeys showed any evidence of protection against challenge, as determined by examination of the resulting parasitemias.


Subject(s)
Antigens, Protozoan/immunology , Antigens, Surface/immunology , Malaria/prevention & control , Plasmodium falciparum/immunology , Protozoan Proteins , Animals , Antibodies, Protozoan/biosynthesis , Antigens, Protozoan/genetics , Antigens, Surface/genetics , Epitopes , Female , Genetic Vectors , Saimiri , Vaccines, Synthetic , Vaccinia virus
12.
Proc Natl Acad Sci U S A ; 88(5): 1751-5, 1991 Mar 01.
Article in English | MEDLINE | ID: mdl-2000383

ABSTRACT

Antigens associated with the surface of merozoites of the malaria parasite Plasmodium falciparum are directly accessible to immune attack and therefore are prime vaccine candidates. We have previously shown that one of the two known merozoite surface antigens (merozoite surface antigen 2; MSA-2) exhibits considerable sequence and antigenic diversity in different isolates. The sequences of MSA-2 from three isolates revealed a central domain composed of repeats that vary in number, length, and sequence, flanked in turn by nonrepetitive variable sequences and by conserved N- and C-terminal domains. We report here the sequences of a further four MSA-2 alleles, containing repetitive sequences that are related but not identical to each other. The seven alleles of MSA-2 can be divided into two distinct allele families on the basis of nonrepetitive sequences. Hybridization studies with repeat probes indicated that all of the 44 P. falciparum isolates examined contained repeat regions similar to those defined in known MSA-2 sequences.


Subject(s)
Antigens, Protozoan/genetics , Antigens, Surface/genetics , Genetic Variation , Plasmodium falciparum/immunology , Amino Acid Sequence , Animals , Base Sequence , Genes , Molecular Sequence Data , Nucleic Acid Hybridization , Oligonucleotide Probes , Plasmodium falciparum/genetics , Polymerase Chain Reaction , Sequence Homology, Nucleic Acid
13.
Mol Biochem Parasitol ; 39(2): 227-34, 1990 Mar.
Article in English | MEDLINE | ID: mdl-2181307

ABSTRACT

An integral membrane protein associated with the merozoite surface of Plasmodium falciparum termed merozoite surface antigen 2 (the 45-kDa merozoite surface antigen), occurs in antigenically diverse forms. Here we report the sequences of the MSA 2 gene from two other isolates of P. falciparum. The 43 N-terminal residues and the 74 C-terminal residues of all three MSA 2 sequences are highly conserved, but between these conserved regions there are dramatic differences among the alleles. Instead of the two copies of a 32-amino-acid repeat present in the MSA 2 of isolate FC27, MSA 2 from clone 3D7 and isolate Indochina 1 contain 5 and 12 copies respectively of the four amino acid sequence Gly Gly Ser Ala. The sequences flanking the repeats also differ among the three antigens. The repeats in MSA 2 appear to be immunodominant during natural infection, and antibodies to the repeat regions of different alleles react with a restricted number of parasite isolates.


Subject(s)
Antigens, Protozoan/genetics , Genetic Variation , Plasmodium falciparum/immunology , Amino Acid Sequence , Animals , Antigens, Protozoan/immunology , Antigens, Surface/genetics , Antigens, Surface/immunology , Base Sequence , Genes , Molecular Sequence Data , Plasmodium falciparum/genetics , Repetitive Sequences, Nucleic Acid , Sequence Homology, Nucleic Acid
15.
Mol Cell Biol ; 9(7): 3151-4, 1989 Jul.
Article in English | MEDLINE | ID: mdl-2701947

ABSTRACT

We describe the cloning of a novel antigen of Plasmodium falciparum which contains a hydrophobic domain typical of an integral membrane protein. This antigen is designated apical membrane antigen 1 because it appears to be located in the apical complex. Apical membrane antigen 1 appears to be transported to the merozoite surface near the time of schizont rupture.


Subject(s)
Antigens, Protozoan/genetics , DNA/genetics , Membrane Proteins/genetics , Plasmodium falciparum/immunology , Amino Acid Sequence , Animals , Base Sequence , Cloning, Molecular , Molecular Sequence Data , Molecular Weight , Plasmodium falciparum/genetics
16.
Proc Natl Acad Sci U S A ; 85(14): 5195-9, 1988 Jul.
Article in English | MEDLINE | ID: mdl-3293051

ABSTRACT

We describe the isolation and cloning of two integral membrane protein antigens of Plasmodium falciparum. The antigens were isolated by Triton X-114 temperature-dependent phase separation, electrophoretically transferred to nitrocellulose, and used to affinity-purify monospecific human antibodies. These antibodies were used to isolate the corresponding cDNA clones from a phage lambda gt11-Amp3 cDNA expression library. Clone Ag512 corresponds to a Mr 55,000 merozoite rhoptry antigen, and clone Ag513 corresponds to a Mr 45,000 merozoite surface antigen. Both proteins can be biosynthetically labeled with [3H]glucosamine and [3H]myristic acid, suggesting that they may be anchored in membranes via a glycosylphosphatidylinositol moiety. Similarities in the C-terminal sequences of the Mr 45,000 merozoite surface antigen and the Trypanosoma brucei variant surface glycoproteins provides further evidence that this antigen has a glycosylphosphatidylinositol anchor.


Subject(s)
Antigens, Protozoan/analysis , Membrane Glycoproteins , Membrane Proteins/analysis , Plasmodium falciparum/immunology , Protozoan Proteins , Amino Acid Sequence , Animals , Antibodies, Protozoan/isolation & purification , Antigens, Protozoan/genetics , Base Sequence , Cloning, Molecular , DNA/genetics , DNA/isolation & purification , DNA, Recombinant/isolation & purification , Electrophoresis, Polyacrylamide Gel , Escherichia coli/genetics , Fluorescent Antibody Technique , Humans , Immunoassay , Immunosorbent Techniques , Membrane Proteins/genetics , Membrane Proteins/immunology , Molecular Sequence Data , Molecular Weight , Phosphatidylinositols/immunology , Sequence Homology, Nucleic Acid
17.
Mol Biochem Parasitol ; 29(1): 77-87, 1988 May.
Article in English | MEDLINE | ID: mdl-3133562

ABSTRACT

Triton X-114 has been employed to isolate integral membrane proteins from Schistosoma japonicum and Schistosoma mansoni adult worms. Suitable marker molecules and antisera directed or raised against schistosome proteins partitioned by Triton X-114 extraction indicated that the phase separation and purification of integral membrane proteins had been successful and this fraction was free of contamination with aqueous (soluble) or secretory antigens. Two dimensional immunoblots further exemplified differences between antigens in the integral membrane protein extract and those of the aqueous fraction. Seven S. japonicum integral membrane proteins have been identified on immunoblots by serum from a hyperimmune and an infected rabbit and by sera from Philippine patients with a history of schistosomiasis japonica. Integral membrane proteins of S. mansoni and S. japonicum had surprisingly little conformity in the molecular weights and electrophoretic mobilities between the two species.


Subject(s)
Antigens, Helminth/analysis , Schistosoma japonicum/immunology , Alkaline Phosphatase/analysis , Animals , Antibody Specificity , Antigens, Helminth/immunology , Antigens, Surface/analysis , Antigens, Surface/immunology , Cross Reactions , Electrophoresis, Polyacrylamide Gel , Humans , Immune Sera , Immunoassay , Schistosoma japonicum/enzymology , Schistosoma mansoni/enzymology , Schistosoma mansoni/immunology , Schistosomiasis japonica/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...